Zogenix, Inc.

If you purchased Zogenix, Inc. securities and would like to join the action, please click "Join This Action" below.

ZOGENIX (ZGNX) STOCK INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ZOGENIX, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – ZGNX

January 19, 2022.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would acquire Zogenix for $26.00 per share in cash, plus a contingent value right for a potential cash payment of $2.00 per share upon EU approval by December 31, 2023, of FINTEPLA®.

The investigation concerns whether Zogenix and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Zogenix shareholders; (2) determine whether UCB is underpaying for Zogenix; and (3) disclose all material information necessary for Zogenix shareholders to adequately assess and value the merger consideration. On behalf of Zogenix shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top